Carbidopa is an antagonistic to peripheral L Dopa Decarboxylation, Carbidopa Doesn’t Cross Blood Brain Barrier. By co-administering Carbidopa, will decrease metabolism of L Dopa in GI Tract / Peripheral Tissues, thereby increasing LDopa conc into CNS; meaning we can decrease L Dopa dose but with less control the adverse effect of the dose. Select one:
[Verified Answer]: Carbidopa is an antagonistic to peripheral…
Need help with your General Clinical Pharmacology case study or NCLEX preparation? Connect with a verified Nursing expert now.
